CA2553402C - Compositions for inhibiting sema7a and vla-1 interaction and methods of using the same - Google Patents

Compositions for inhibiting sema7a and vla-1 interaction and methods of using the same Download PDF

Info

Publication number
CA2553402C
CA2553402C CA2553402A CA2553402A CA2553402C CA 2553402 C CA2553402 C CA 2553402C CA 2553402 A CA2553402 A CA 2553402A CA 2553402 A CA2553402 A CA 2553402A CA 2553402 C CA2553402 C CA 2553402C
Authority
CA
Canada
Prior art keywords
vla
sema7a
cell
compound
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2553402A
Other languages
French (fr)
Other versions
CA2553402A1 (en
Inventor
Hitoshi Kikutani
Atsushi Kumanogoh
Kenji Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Osaka University NUC
Original Assignee
Boehringer Ingelheim International GmbH
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Osaka University NUC filed Critical Boehringer Ingelheim International GmbH
Priority to CA2553402A priority Critical patent/CA2553402C/en
Publication of CA2553402A1 publication Critical patent/CA2553402A1/en
Application granted granted Critical
Publication of CA2553402C publication Critical patent/CA2553402C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed are compositions and methods of treating a cytokine mediated disease by inhibiting Sema7A with VLA-1. Also disclosed are methods to identify a compound that inhibits interaction of Sema7A with VLA-1. Such methods involve (1) contacting a cell with a putative regulatory compound; and (2) assessing the ability of the compound to inhibit the interaction of Sema7A with VLA-1. Step (1) may employ a cell that includes a Sema7A
protein and a VLA-1 protein. Step (1) may also employ a cell that includes a Sema7A
protein, and the cell is contacted with the compound and VLA-1. Step (1) may also employ a cell that includes a VLA-1 protein, and the cell is contacted with the compound and Sema7A.

Claims (3)

CLAIMS:
1. A method to identify a compound that inhibits interaction of Sema7A with VLA-1, comprising: (1) contacting a cell with a putative regulatory compound, wherein the cell includes a Sema7A protein and a VLA-1 protein; and (2) assessing the ability of the putative regulatory compound to inhibit the interaction of Sema7A with VLA-1.
2. A method to identify a compound that inhibits interaction of Sema7A with VLA-1, comprising: (1) contacting a cell with a putative regulatory compound and VLA-1, wherein the cell includes a Sema7A protein; and (2) assessing the ability of the putative regulatory compound to inhibit the interaction of Sema7A with VLA-1.
3. A method to identify a compound that inhibits interaction of Sema7A with VLA-1, comprising: (1) contacting a cell with a putative regulatory compound and Sema7A, wherein the cell includes a VLA-1 protein; and (2) assessing the ability of the putative regulatory compound to inhibit the interaction of Sema7A with VLA-1.
CA2553402A 2006-07-25 2006-07-25 Compositions for inhibiting sema7a and vla-1 interaction and methods of using the same Active CA2553402C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2553402A CA2553402C (en) 2006-07-25 2006-07-25 Compositions for inhibiting sema7a and vla-1 interaction and methods of using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2553402A CA2553402C (en) 2006-07-25 2006-07-25 Compositions for inhibiting sema7a and vla-1 interaction and methods of using the same

Publications (2)

Publication Number Publication Date
CA2553402A1 CA2553402A1 (en) 2008-01-25
CA2553402C true CA2553402C (en) 2014-10-14

Family

ID=38973681

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2553402A Active CA2553402C (en) 2006-07-25 2006-07-25 Compositions for inhibiting sema7a and vla-1 interaction and methods of using the same

Country Status (1)

Country Link
CA (1) CA2553402C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156890B (en) * 2019-04-09 2021-02-02 苏州大学 Semaphorin7A monoclonal antibody and application thereof in preparation of drugs for treating inflammatory diseases

Also Published As

Publication number Publication date
CA2553402A1 (en) 2008-01-25

Similar Documents

Publication Publication Date Title
WO2007101225A3 (en) Methods to identify inhibitors of the unfolded protein response
MX2007007588A (en) Tetrahydroquinoline analogues as muscarinic agonists.
WO2007089318A3 (en) Compositions and methods for reducing food cravings
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
NO20074509L (en) Combination of organic compounds
WO2008069889A3 (en) Methods of treating hemolytic anemia
WO2005074607A3 (en) Method of treating hemolytic disease
WO2007112288A3 (en) Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2006050012A3 (en) Morinda citrifolia based compositions and methods for inhibiting xanthine oxidase
EA200870029A1 (en) METHOD OF APPLICATION OF IL-6 ANTAGONISTS WITH PROTEAS INHIBITORS
WO2005089737A3 (en) Materials and methods for inhibiting wip1
NO20083918L (en) Dihydridiazepines useful as inhibitors of protein kinases
WO2007079164A3 (en) Protein kinase inhibitors
WO2007026251A3 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2007009071A3 (en) Methods of diagnosing and treating an inflammatory response
WO2007112015A3 (en) Phenolic hydrazone macrophage migration inhibitory factor inhibitors
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2007024921A3 (en) Combination therapies for inhibiting integrin-extracellular matrix interactions
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2007082177A3 (en) Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity
WO2006041835A3 (en) Methods of inhibiting cell death or inflammation in a mammal
WO2010005565A3 (en) Method of treating glycogen storage disease

Legal Events

Date Code Title Description
EEER Examination request